Catalyst Pharmaceuticals (CPRX) Retained Earnings (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Retained Earnings data on file, last reported at $489.2 million in Q1 2026.

• Quarterly Retained Earnings rose 2877852.94% year-over-year to $489.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $489.2 million (up 2877852.94% YoY) and the FY2025 annual result came in at $480.0 million, up 749832.81% from the prior year.
• Retained Earnings rose to $489.2 million in Q1 2026, from $480.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $489.2 million in Q1 2026 to a low of -$453000.0 in Q1 2022.
• A 5-year average of $103.0 million and a median of $21500.0 in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 251.35% — and 2026, when it surged 2877852.94%.
• Tracing CPRX's Retained Earnings over 5 years: stood at $24000.0 in 2022, then sank by 41.67% to $14000.0 in 2023, then soared by 357.14% to $64000.0 in 2024, then surged by 749832.81% to $480.0 million in 2025, then advanced by 1.93% to $489.2 million in 2026.
• The last three Retained Earnings figures came in at $489.2 million (Q1 2026), $480.0 million (Q4 2025), and $473.3 million (Q3 2025), per Business Quant data.